ClinicalTrials.gg
RecruitingNCT05910398CORINNE-PIUpdated Nov 18, 2025

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

A Phase 3 interventional study of pyrotinib in Breast Cancer Invasive, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by RenJi Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing pyrotinib in Breast Neoplasms — 49 open to participants now, 57 under way, 13 of them phase 3. pyrotinib · Breast Neoplasms.

Planned enrollment
12th of 101
488 · median 100
Started
2023
with 7 others
Phase 3
17 of 101
10 open now
Primary completion
2030-04
later than 51 of 56 live
Registered
74th of 101
by date

Among the 101 studies testing pyrotinib in Breast Neoplasms, this one is the 12th largest by planned enrollment, is one of 8 that started in 2023, is one of 17 in phase 3, reaches primary completion later than 51 of the 56 other live ones, and was the 74th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

49 of the 101 studies testing pyrotinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 49 open studies →

Where they have run

About pyrotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing pyrotinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

03

Conditions studied

  • Breast Cancer Invasive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18;
  • confirmed invasive positive breast cancer;
  • Duration from random time to the last use of trastuzumab or T-DM1 ≤3 years;
  • Performance Status- (ECOG) 0-1;
  • Adequate organ functions.

Exclusion criteria

Exclusion Criteria:

  • disease (Stage IV);
  • Gross residual disease remaining after mastectomy or positive margins after breast-conserving surgery;
  • Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption;
  • Treated or treating with anti- tyrosine kinase inhibitor;
  • Less than 4 weeks from the last clinical trial;
  • History of immunodeficiency, including -positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation;
  • Female patients who are pregnancy, lactation or women who are of tested positive in baseline pregnancy test; Female patients of childbearing age that are reluctant to take effective measures throughout the trial period;
  • Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
488 participants (estimated)

Study arms

  • Active comparator
    continuous pyrotinib

    pyrotinib 400 mg, orally once daily for one year

    Drug: pyrotinib

  • Experimental
    intermittent pyrotinib

    pyrotinib 400 mg, 14 days on and 7 days off, every 21 days for 17 cycles

    Drug: pyrotinib

Interventions

  • an irreversible anti-HER2 tyrosine kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival (iDFS)

    Invasive disease-free survival time is defined as the time from date of randomization until the first invasive disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause.

    Time frame: From randomization until time of event up to 2 years.

Secondary outcomes

  1. Disease-free Survival (DFS)

    Disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, non-breast primary invasive cancer, ductal carcinoma in situ (DCIS),or distant recurrence and death from any cause

    Time frame: From randomization until time of event up to 2 years

  2. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause.

    Time frame: From randomization until time of event up to 2 years

  3. Adverse events

    Adverse events will be assessed according to the NCI CTCAE v5.0.

    Time frame: From the date of starting pyrotinib to the end of the treatment (up to approximately 1 year)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2030, 82 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 82 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 18, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Apr 2030
CompletionEst.
Aug 2030
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05910398
Lead sponsor
RenJi Hospital
Responsible party
Wenjin Yin (Deputy Chief of Breast Surgery Department, RenJi Hospital) — Principal investigator
First posted
Jun 18, 2023
Start date
Jun 1, 2023
Primary completion
Apr 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Nov 18, 2025

Study contacts

Wenjin Yin, M.D.
Contact
yinwenjin@renji.com
86(21)58852345
Qi Lu
Contact
rjllb3364@163.com
86(21)68383364
Wenjin Yin, M.D.
principal investigator · Renji Hospital, School of Medicine, Shanghai Jiao Tong University.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrotinib

Start the discussion